CCO Infectious Disease Podcast

Modifying ART in the Presence of Hyperlipidemia: Using HIV-ASSIST

Episode Summary

HIV is a risk-enhancing factor that favors initiation of statin therapy when it coexists with hyperlipidemia. Hear how Maunank Shah, MD, PhD, uses HIV-ASSIST to optimize management of both hyperlipidemia and HIV.

Episode Notes

In this episode, Maunank Shah, MD, PhD, discusses using HIV-ASSIST to optimize treatment for both HIV and hyperlipidemia. Listen as he covers:

• Hyperlipidemia and cardiovascular disease risk among people living with HIV
• Recommendations for lipid screening for people living with HIV
• Using HIV-ASSIST to support ART treatment decisions for people living with HIV with comorbidities
• How HIV-ASSIST prioritizes certain ART agents in the setting of hyperlipidemia, including:
  • Deciding between bictegravir, doravirine, dolutegravir, raltegravir, and rilpivirine vs boosted protease inhibitors, including darunavir
  • Deciding between tenofovir disoproxil fumarate and tenofovir alafenamide or abacavir
• How HIV-ASSIST incorporates drug‒drug interaction data from the University of Liverpool HIV Drug Interactions Checker and the DHHS guidelines when considering the use of statin therapy with ART
• How HIV-ASSIST further incorporates drug resistance data from the Stanford HIV Drug Resistance Database

Maunank Shah, MD, PhD 
Associate Professor 
Infectious Diseases 
Johns Hopkins University 
Baltimore, Maryland 

Link to full program: bit.ly/3pwaH2Y